Carisma Therapeutics secures Nasdaq listing extension with transfer to Capital Market, strict conditions to Oct 7, 2025

Carisma Therapeutics Inc.

Nasdaq Panel granted exception; listing transferred to Nasdaq Capital Market effective June 12, 2025.
Must demonstrate closing bid price ≥$1.00 for 10 consecutive sessions by Oct 7, 2025.
Must complete a strategic transaction and meet all initial listing requirements for Capital Market by Oct 7.
Company had previously failed MVLS ($50M), MVPHS ($15M), and Bid Price ($1.00) rules.
Panel may reconsider if conditions not met; no assurance of compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.